• Achieved 15,000 contracted licenses and $5.6M contracted ARR as of 30th September 2025
• Received FDA De Novo clearance for PainChek Adult, enabling entry into $175M annual US long-term care market
• Launched PainChek Infant, the world's first AI-enabled app for instant pain assessment on infants aged 1-12 months

PainChek Ltd, a leading provider of pain assessment technology, presented an update at its Annual General Meeting. The company highlighted several key achievements in the past year, including reaching 15,000 contracted licenses and $5.6M contracted annual recurring revenue (ARR) as of 30th September 2025. The company's adult app also received FDA De Novo clearance, enabling it to enter the $175M annual US long-term care market. PainChek also launched its new PainChek Infant app, the world's first AI-enabled app for instant pain assessment on infants aged 1-12 months. The company outlined its plans for continued growth, including building a sales pipeline in the US market, expanding partnerships to cover 80% of long-term care beds, and finalizing market entry strategies for Australia, the UK, Canada, and Germany. Additionally, the company is developing new products and technologies, such as apps for toddlers, vocalisation assessment, and a prototype for the disabilities market.

PainChek is targeting 10% penetration of the US long-term care market and aims to achieve operational break-even in Australia and the UK by Q4 CY2026.

PainChek is focused on continued growth of its adult app in key markets, entering the US market, and commercializing its new infant pain assessment technology globally. The company is also developing additional products and technologies to expand its offerings.